Alvotech (ALVO) earnings

Alvotech earnings: last reported Thu, 20 Aug 2026, for the quarter ended Jun 2026.

Alvotech earnings calls

Alvotech earnings calls (ALVO)

Latest concall · Q2 2026 · call held 20 Aug 2026

Alvotech Q2 FY26 — Regulatory Progress and Portfolio Expansion Drive Future Growth

What went well

U.S. BLA resubmissions for AVT-05, AVT-06, and Prolia/XGEVA biosimilar in June 2026, paving the way for FDA approvals in Q4 2026.
FDA formally closed the GMP surveillance inspection of the manufacturing facility with a VAI classification in July 2026.
Successful equity financing completed in June 2026 generated approximately $165 million in gross proceeds, strengthening the cash position to $143 million.

What to watch

Total revenue for H1 2026 declined 31% to $212 million compared to $306 million in H1 2025, primarily due to manufacturing slowdowns.
Adjusted EBITDA for H1 2026 decreased to $46 million compared to $54 million in H1 2025.

Read the full call →

Performance −31.0% 1Y

1Y: $8.4 on 29 Sept 2025 → $5.8. High $8.98 (15 Oct 2025), low $3 (2 Jun 2026).

Balance sheet

Year ending	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total liabilities	—	$733.59M	$1.39B	$1.88B	$1.63B	$1.77B
Fixed assets	—	$78.53M	$220.59M	$236.78M	$284.55M	$356.40M
Total assets	—	$597.98M	$828.44M	$950.09M	$1.22B	$1.49B

How to read this

As filed on each reporting date, including interim balance sheets. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Insider filings

No filings in the last 12 months.

No officer, director or 10% owner of ALVO filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.